meningococcal infections

Summary

Summary: Infections with bacteria of the species NEISSERIA MENINGITIDIS.

Top Publications

  1. Mothibeli K, du Plessis M, Von Gottberg A, Murphy E, Hoiseth S, Zlotnick G, et al. Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine. 2011;29:2187-92 pubmed publisher
    ..Our data highlight that non-MenB meningococcal isolates also harbor fHBP...
  2. Fransen F, Hamstra H, Boog C, van Putten J, van den Dobbelsteen G, van der Ley P. The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease. Infect Immun. 2010;78:3177-86 pubmed publisher
    ..These results demonstrate the crucial role of N. meningitidis lipid A structure in virulence...
  3. Close R, Ejidokun O, Verlander N, Fraser G, Meltzer M, Rehman Y, et al. Early diagnosis model for meningitis supports public health decision making. J Infect. 2011;63:32-8 pubmed publisher
    ..To develop a predictive model for rapid differential diagnosis of meningitis and meningococcal septicaemia to support public health decisions on chemoprophylaxis for contacts...
  4. Ram S, Lewis L, Rice P. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010;23:740-80 pubmed publisher
    ..Paramount to the management of patients with complement deficiencies and asplenia is educating patients about their predisposition to infection and the importance of preventive immunizations and seeking prompt medical attention...
  5. Deghmane A, Parent Du Chatelet I, Szatanik M, Hong E, Ruckly C, Giorgini D, et al. Emergence of new virulent Neisseria meningitidis serogroup C sequence type 11 isolates in France. J Infect Dis. 2010;202:247-50 pubmed publisher
    ..These isolates may be responsible for a peak in the incidence of serogroup C meningococcal infection in France, for which there is no routine vaccination to date...
  6. Joseph B, Schneiker Bekel S, Schramm Glück A, Blom J, Claus H, Linke B, et al. Comparative genome biology of a serogroup B carriage and disease strain supports a polygenic nature of meningococcal virulence. J Bacteriol. 2010;192:5363-77 pubmed publisher
  7. Chacon Cruz E, Sugerman D, Ginsberg M, Hopkins J, Hurtado Montalvo J, Lopez Viera J, et al. Surveillance for invasive meningococcal disease in children, US-Mexico border, 2005-2008. Emerg Infect Dis. 2011;17:543-6 pubmed publisher
    ..The overall incidence and fatality rate observed in Tijuana were similar to those found in the US, and serogroup distribution suggests that most cases in Tijuana are vaccine preventable...
  8. Vu D, Shaughnessy J, Lewis L, Ram S, Rice P, Granoff D. Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect Immun. 2012;80:643-50 pubmed publisher
  9. Gossger N, Snape M, Yu L, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573-82 pubmed publisher
    ..In the absence of an effective vaccine, serogroup B Neisseria meningitidis (MenB) remains a major cause of invasive disease in early childhood in developed countries...

More Information

Publications64

  1. Holst J, Nøkleby H, Bettinger J. Considerations for controlling invasive meningococcal disease in high income countries. Vaccine. 2012;30 Suppl 2:B57-62 pubmed publisher
    ..We also offer a series of recommendations to address possible concerns about vaccine safety...
  2. Djingarey M, Barry R, Bonkoungou M, Tiéndrebéogo S, Sebgo R, Kandolo D, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine. 2012;30 Suppl 2:B40-5 pubmed publisher
    ..The Burkina Faso success augurs well for further rollout of the Men A conjugate vaccine in meningitis belt countries...
  3. Bai X, Borrow R. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev Vaccines. 2010;9:1203-17 pubmed publisher
    ..The outlook for the quest for broadly cross-protective meningococcal serogroup B vaccine components in the postgenomic era will be discussed...
  4. Caron F, Delbos V, Houivet E, Deghmane A, Leroy J, Hong E, et al. Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac. Vaccine. 2012;30:5059-62 pubmed publisher
    ..1% 6 weeks after the completion of the schedule, but declined to 39.7% one year later. This level is lower than the targeted 60% level and suggests only short-term persistence of response against B:14:P1.7,16 using this schedule...
  5. Kristiansen P, Diomande F, Wei S, Ouédraogo R, Sangare L, Sanou I, et al. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol. 2011;18:435-43 pubmed publisher
    ..5-1,2-2/F5-8, belonging to the ST-23 complex (47%). All serogroup A isolates were ST-2859 of the ST-5 complex with P1.20,9/F3-1. This study forms a solid basis for evaluating the impact of MenAfriVac introduction on serogroup A carriage...
  6. Christensen H, May M, Bowen L, Hickman M, Trotter C. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853-61 pubmed publisher
    ..Previous studies have shown that carriage rates vary by age and setting; however, few have assessed carriage across all ages. We aimed to estimate the age-specific prevalence of meningococcal carriage...
  7. Ibarz Pavón A, Lemos A, Gorla M, Regueira M, Gabastou J. Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010. PLoS ONE. 2012;7:e44102 pubmed publisher
  8. Brandtzaeg P, van Deuren M. Classification and pathogenesis of meningococcal infections. Methods Mol Biol. 2012;799:21-35 pubmed publisher
    ..Despite rapid intervention and advances in patient intensive care, why as many as 30% of patients with systemic meningococcal disease develop massive meningococcemia leading to shock and death is still not understood...
  9. Echenique Rivera H, Muzzi A, Del Tordello E, Seib K, Francois P, Rappuoli R, et al. Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog. 2011;7:e1002027 pubmed publisher
    ..This increased knowledge of how Nm responds to adaptation in blood could also be helpful to develop diagnostic and therapeutic strategies to control the devastating disease cause by this microorganism...
  10. Christensen H, Hickman M, Edmunds W, Trotter C. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31:2638-46 pubmed publisher
  11. Santolaya M, O Ryan M, Valenzuela M, Prado V, Vergara R, Munoz A, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379:617-24 pubmed publisher
    ..We assessed immunogenicity and tolerability of a four-component vaccine (4CMenB) in adolescents...
  12. Cehovin A, Winterbotham M, Lucidarme J, Borrow R, Tang C, Exley R, et al. Sequence conservation of pilus subunits in Neisseria meningitidis. Vaccine. 2010;28:4817-26 pubmed publisher
    ..These data have important implications for the re-consideration of pilus subunits as vaccine antigens...
  13. Caugant D, Kristiansen P, Wang X, Mayer L, Taha M, Ouédraogo R, et al. Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS ONE. 2012;7:e46019 pubmed publisher
  14. Safadi M, McIntosh E. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies. Expert Rev Vaccines. 2011;10:1717-30 pubmed publisher
    ..Vaccination policies to prevent meningococcal disease in different regions of the world should be based on quality information from enhanced surveillance systems...
  15. Ladhani S, Flood J, Ramsay M, Campbell H, Gray S, Kaczmarski E, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30:3710-6 pubmed publisher
  16. Johswich K, Zhou J, Law D, St Michael F, McCaw S, Jamieson F, et al. Invasive potential of nonencapsulated disease isolates of Neisseria meningitidis. Infect Immun. 2012;80:2346-53 pubmed publisher
    ..Our results suggest the acquisition of a new virulence phenotype by these nonencapsulated strains...
  17. Yogev R, Tan T. Meningococcal disease: the advances and challenges of meningococcal disease prevention. Hum Vaccin. 2011;7:828-37 pubmed publisher
  18. Tala A, Monaco C, Nagorska K, Exley R, Corbett A, Zychlinsky A, et al. Glutamate utilization promotes meningococcal survival in vivo through avoidance of the neutrophil oxidative burst. Mol Microbiol. 2011;81:1330-42 pubmed publisher
    ..We show that this mechanism contributes to the ability of N. meningitidis to cause bacteraemia, a critical step in the disease process during infections caused by this important human pathogen...
  19. Caron F, du Châtelet I, Leroy J, Ruckly C, Blanchard M, Bohic N, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11:455-63 pubmed publisher
    ..Outer-membrane-vesicle vaccines for meningococcal B outbreaks are complex and time consuming to develop. We studied the use of already available vaccine to control an outbreak caused by a genetically close strain...
  20. Andrews S, Pollard A. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. Lancet Infect Dis. 2014;14:426-34 pubmed publisher
  21. Davila S, Wright V, Khor C, Sim K, Binder A, Breunis W, et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet. 2010;42:772-6 pubmed publisher
    ..Our study suggests that host genetic variation in these regulators of complement activation plays a role in determining the occurrence of invasive disease versus asymptomatic colonization by this pathogen...
  22. Lucidarme J, Tan L, Exley R, Findlow J, Borrow R, Tang C. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol. 2011;18:1002-14 pubmed publisher
    ..No fH binding was detected to other ligands among the fHbp-negative strains. The implications of these findings for meningococcal pathogenesis and prevention are discussed...
  23. van de Waterbeemd B, Streefland M, van der Ley P, Zomer B, van Dijken H, Martens D, et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine. 2010;28:4810-6 pubmed publisher
    ..With comparable toxicity and yield, no aggregation and cross-protection against other PorA subtypes, these OMV vaccines are potentially safe and effective for parenteral use in humans...
  24. Dupin N, Lecuyer H, Carlotti A, Poyart C, Coureuil M, Chanal J, et al. Chronic meningococcemia cutaneous lesions involve meningococcal perivascular invasion through the remodeling of endothelial barriers. Clin Infect Dis. 2012;54:1162-5 pubmed publisher
    ..Both in vivo and in vitro data suggest that, in these lesions, meningococci gain access from the capillary lumen to the peripheral extravascular compartment, in the absence of vascular dislocation, through a paraendothelial route...
  25. Zhou J, Lefebvre B, Deng S, Gilca R, Deceuninck G, Law D, et al. Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J Clin Microbiol. 2012;50:1545-51 pubmed publisher
    ..However, one ST (ST-571), which is uncommon in the United States, accounted for 35% of all cases due to this CC. The current finding suggests that the ST-269 clone may indeed represent an emerging hypervirulent clone of meningococci...
  26. Lucidarme J, Newbold L, Findlow J, Gilchrist S, Gray S, Carr A, et al. Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP. Clin Vaccine Immunol. 2011;18:194-202 pubmed publisher
  27. Bidmos F, Neal K, Oldfield N, Turner D, Ala Aldeen D, Bayliss C. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol. 2011;49:506-12 pubmed publisher
    ..Rapid clonal expansion of potentially pathogenic strains in residential halls has implications for the implementation of public health interventions in university populations...
  28. Tauseef I, Harrison O, Wooldridge K, Feavers I, Neal K, Gray S, et al. Influence of the combination and phase variation status of the haemoglobin receptors HmbR and HpuAB on meningococcal virulence. Microbiology. 2011;157:1446-56 pubmed publisher
    ..We suggest that expression of a haemoglobin receptor, either HmbR or HpuAB, is of major importance for systemic spread of meningococci, and that the presence of both receptors contributes to virulence in some strains...
  29. De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J. 2011;30:566-9 pubmed publisher
    ..In 2002, 1 C-MCV dose was routinely offered to children 12 months of age...
  30. Bertrand S, Van Meervenne E, de Baere T, Vanhoof R, Collard J, Ruckly C, et al. Detection of a geographical and endemic cluster of hyper-invasive meningococcal strains. Microbes Infect. 2011;13:684-90 pubmed publisher
    ..This study showed that the combination of molecular tools with classical methods enabled reliable outbreak detection as well as a cluster identification...
  31. Nieto Guevara J, Luciani K, Montesdeoca Melían A, Mateos Durán M. Epidemiology of meningococcal disease in the Panamanian pediatric population, 1998-2008. J Infect Dev Ctries. 2011;5:318-23 pubmed
    ..This study describes the epidemiology, microbiology, and clinical presentation of this disease in the Panamanian pediatric population...
  32. Harrison L, Pelton S, Wilder Smith A, Holst J, Safadi M, Vazquez J, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29:3363-71 pubmed publisher
    ..Innovative approaches are needed to introduce and sustain meningococcal vaccination programs in resource-poor settings with a high incidence of meningococcal disease...
  33. Jiang H, Hoiseth S, Harris S, McNeil L, Zhu D, Tan C, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28:6086-93 pubmed publisher
    ..Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed...
  34. Tunio S, Oldfield N, Ala Aldeen D, Wooldridge K, Turner D. The role of glyceraldehyde 3-phosphate dehydrogenase (GapA-1) in Neisseria meningitidis adherence to human cells. BMC Microbiol. 2010;10:280 pubmed publisher
  35. Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011;11:969-85 pubmed publisher
    ..The novel vaccine Bexsero (previously 4CMenB) has been developed and proven safe and immunogenic in clinical trials...
  36. Halperin S, Bettinger J, Greenwood B, Harrison L, Jelfs J, Ladhani S, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30 Suppl 2:B26-36 pubmed publisher
    ..Continued surveillance of meningococcal disease is essential; ongoing global efforts to improve the completeness of reporting are required...
  37. Szatanik M, Hong E, Ruckly C, Ledroit M, Giorgini D, Jopek K, et al. Experimental meningococcal sepsis in congenic transgenic mice expressing human transferrin. PLoS ONE. 2011;6:e22210 pubmed publisher
    ..This new approach should enable detailed analysis of the pathophysiology of meningococcal sepsis and its relationships with flu infection...
  38. Memish Z, Goubeaud A, Broker M, Malerczyk C, Shibl A. Invasive meningococcal disease and travel. J Infect Public Health. 2010;3:143-51 pubmed publisher
    ..This review presents the global epidemiology of meningococcal disease, and discusses prophylaxis options including meningococcal ACWY vaccines...
  39. Su E, Snape M. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines. 2011;10:575-88 pubmed publisher
    ..In this article, we will review recent advances in the development of these vaccines, focussing particularly on one of the 'next generation' MenB vaccines, 4CMenB...
  40. Coureuil M, Lecuyer H, Scott M, Boularan C, Enslen H, Soyer M, et al. Meningococcus Hijacks a ?2-adrenoceptor/?-Arrestin pathway to cross brain microvasculature endothelium. Cell. 2010;143:1149-60 pubmed publisher
    ..The identification of the mechanism used for hijacking host cell signaling machineries opens perspectives for treatment and prevention of meningococcal infection...
  41. Harris S, Zhu D, Murphy E, McNeil L, Wang X, Mayer L, et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease. Hum Vaccin. 2011;7 Suppl:68-74 pubmed
    ..These promising findings suggest that a bivalent fHBP vaccine may be capable of providing protection against meningococcal disease caused by both serogroup C and B...
  42. van de Waterbeemd B, Streefland M, van Keulen L, van den IJssel J, de Haan A, Eppink M, et al. Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis. Vaccine. 2012;30:3683-90 pubmed publisher
    ..High functional immunogenicity and low toxicity of the optimized vaccine were also confirmed. The EDTA extraction is therefore a robust process step which produces high quality OMV if harvest and pH are controlled accurately...
  43. Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil J, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29:4739-44 pubmed publisher
  44. Harrison O, Claus H, Jiang Y, Bennett J, Bratcher H, Jolley K, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19:566-73 pubmed publisher
    ..In this report, a comprehensive description of all N. meningitidis serogroups is provided, along with a proposed nomenclature, which was presented at the 2012 XVIIIth International Pathogenic Neisseria Conference. ..
  45. Arnold R, Galloway Y, McNicholas A, O Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011;29:7100-6 pubmed publisher
    ..Between July 2004 and December 2008 an estimated 210 epidemic strain cases (95% CI 100-380), six deaths and 15-30 cases of severe sequelae were avoided in New Zealand due to the introduction of the MeNZB vaccine...
  46. Bryant K, Marshall G, Marchant C, Pavia Ruiz N, Nolan T, Rinderknecht S, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics. 2011;127:e1375-85 pubmed publisher
    ..A phase III study evaluated the immunogenicity and safety of an investigational Haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY)...
  47. Sinclair D, Preziosi M, Jacob John T, Greenwood B. The epidemiology of meningococcal disease in India. Trop Med Int Health. 2010;15:1421-35 pubmed publisher
    ..To undertake a review of the literature on the epidemiology of meningococcal disease in India, with a view to informing future control policies...
  48. Tuite A, Kinlin L, Kuster S, Jamieson F, Kwong J, Mcgeer A, et al. Respiratory virus infection and risk of invasive meningococcal disease in central Ontario, Canada. PLoS ONE. 2010;5:e15493 pubmed publisher
  49. Ladhani S, Lucidarme J, Newbold L, Gray S, Carr A, Findlow J, et al. Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. Emerg Infect Dis. 2012;18:63-70 pubmed publisher
    ..The increase in MenY disease requires careful epidemiologic and molecular monitoring...
  50. Viner R, Booy R, Johnson H, Edmunds W, Hudson L, Bedford H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11:774-83 pubmed publisher
    ..Assessment of new serogroup B meningococcal vaccines is hampered by a scarcity of data on the burden of disease in survivors. We aimed to estimate the disease burden in children having survived serogroup B meningococcal disease...
  51. Murray R, Britton J, Leonardi Bee J. Second hand smoke exposure and the risk of invasive meningococcal disease in children: systematic review and meta-analysis. BMC Public Health. 2012;12:1062 pubmed publisher
  52. Darton T, Guiver M, Naylor S, Jack D, Kaczmarski E, Borrow R, et al. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis. 2009;48:587-94 pubmed publisher
    ..meningitidis serogroup C than in those infected with other serogroups. The effects of age and IL-1 genotype on mortality are independent of a high genomic bacterial load. ..
  53. Coulson G, Von Gottberg A, du Plessis M, Smith A, de Gouveia L, Klugman K. Meningococcal disease in South Africa, 1999-2002. Emerg Infect Dis. 2007;13:273-81 pubmed
    ..Selected isolates of serogroup A belonged to sequence type (ST)-1 (subgroup I/II) complex, serogroup B to ST-32/electrophoretic type (ET)-5 complex, and serogroup W135 to ST-11/ET-37 complex. ..
  54. Kelly C, Arnold R, Galloway Y, O Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol. 2007;166:817-23 pubmed
    ..In a sensitivity analysis, these estimates proved to be robust to modeling assumptions, including population estimates, estimates of the numbers vaccinated, effects of partial vaccination, and temporal autocorrelation...
  55. Elias J, Claus H, Frosch M, Vogel U. Evidence for indirect nosocomial transmission of Neisseria meningitidis resulting in two cases of invasive meningococcal disease. J Clin Microbiol. 2006;44:4276-8 pubmed
    ..The most likely epidemiological link was simultaneous hospitalization, resulting in indirect nosocomial transmission...